Joining Peter D. Parker on the Cequent Pharmaceuticals, Inc. Board of Directors are:

Chiang J. Li, M.D.

Founder, Director and Chairman of Scientific Advisory Board

Dr. Li is President and Chief Executive Officer, Boston Biomedical, Inc. He is also an adjunct faculty member at Beth Israel Deaconess Medical Center, Harvard Medical School. From September 2003 to January 2007, Dr. Li was Chief Scientific Officer, Executive Vice President and Head of ArQule Biomedical Institute, ArQule Inc (Nasdaq:ARQL). He is the Chairman of ArQule’s scientific advisory board.  Dr. Li joined ArQule in September 2003. He previously served as the scientific founder and Vice President of Research at Cyclis Pharmaceuticals, Inc., an Ampersand Ventures portfolio company. Dr. Li was a faculty member of Harvard Medical School, a physician and the Head of a GI Cancer Laboratory at the Beth Israel Deaconess Medical Center, Harvard Medical School. 

His research team at Harvard invented transkingdom RNAi technology, which promises to accelerate biomedical research and medical therapies based on RNA interference. He is a recipient of a number of awards and recognitions, and has published numerous highly cited articles in top leading science journals. Dr. Li graduated from the Harvard-MIT Division of Health Science and Technology and received his M.D. degree Magna Cum Laude from Harvard Medical School, completed medical residency and fellowship at Harvard’s Brigham Women’s Hospital/Dana-Farber Cancer Institute and Beth Israel Deaconess Medical center, and is a diplomate of the American Board of Internal Medicine.

Herbert H. Hooper, Ph.D.

General Partner, Ampersand Ventures

Dr. Hooper is a General Partner at Ampersand Ventures. Prior to joining Ampersand in 2002, Dr. Hooper served as executive vice president and chief technical officer of ACLARA BioSciences, a public life sciences company which he founded in 1995. From 1993 to 1995, Dr. Hooper served as a research director at Soane Technologies, Inc. From 1990 to 1993, he served in various product and business development positions at Air Products and Chemicals. Dr. Hooper currently serves as chairman of the board of RadPharm, Inc. and Magellan BioSciences, Inc., both of which are private life sciences companies. Dr. Hooper also serves on the board of Assay Designs, Inc., IBT Reference Lab, and Medifacts, and Panacos Pharmaceuticals, Inc. He previously served as a member of the board of directors of ACLARA BioSciences and Cyclis Pharmaceuticals. Dr. Hooper holds a B.S. in Chemical Engineering from North Carolina State University and a Ph.D. in Chemical Engineering from the University of California, Berkeley.

Thomas Hancock

Principal, New England Partners

Prior to joining New England Partners, Mr. Hancock was a Senior Analyst and Managing Director at U.S. Bancorp Piper Jaffray, responsible for covering biopharmaceuticals and drug discovery tools. Previously, Mr. Hancock was a biotech analyst at NationsBanc Montgomery; was one of the early management employees at COR Therapeutics, Inc.; and was in laboratory research and business development at Genentech, Inc. He holds a BS, Molecular Biology and an MBA, both from UC Berkeley.

Steven Tregay, Ph.D.

Managing Director, Novartis Option Fund

Dr. Tregay is a Managing Director of the newly launched $200 million Novartis Option Fund. Prior to joining the venture group, he was the Executive Director and Head of Strategic Alliances – oncology, ophthalmology, and technologies at the Novartis Institutes for BioMedical Research. Prior to joining Novartis, Dr. Tregay held various roles in both business development and research. He holds doctorate and master’s degrees in organic chemistry from Harvard University and a bachelor’s from Davidson College, in North Carolina.

Eric W. Linsley

Partner, Pappas Ventures

Mr. Linsley is an experienced operating executive and venture capital investor who prior to joining Pappas in 2000 served as Chief Financial Officer of TriPath Imaging, Inc. (Nasdaq: TPTH), a medical device company. Mr. Linsley played a key role in the three-way merger between AutoCyte, NeoPath and Neuromedical Systems that created TriPath. Prior to the merger, he served as Chief Financial Officer and Vice President of Operations at AutoCyte where he led the company in a successful public equity offering in 1997. From 1991 to 1997, Mr. Linsley worked as an investment professional with Ampersand Ventures, a leading venture capital firm based in Boston. As a partner at Ampersand, he held interim management positions in operating and financial roles for various industrial products and healthcare companies. He previously served as a management consultant with Bain & Co. and McKinsey & Co., and was a certified public accountant with Arthur Andersen LLP. Mr. Linsley is a director of Emerald BioAgriculture, FlowCardia, and Sensys Medical. He is also a director of Panacos Pharmaceuticals (Nasdaq: PANC), and played a key role in its successful reverse merger with a publicly-traded company. He was directly responsible for the investment by Pappas Ventures II in Peninsula Pharmaceuticals, which Johnson & Johnson acquired in 2005 at a substantial premium. He is also a board observer at LipoScience. Mr. Linsley received his BA in Economics from Trinity College, an MS in Accounting from New York University and an MBA from Wharton School at the University of Pennsylvania.